サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1546190

ラジオイムノアッセイの世界市場

Radioimmunoassays

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
ラジオイムノアッセイの世界市場
出版日: 2024年09月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ラジオイムノアッセイの世界市場は2030年までに5億8,710万米ドルに達する見込み

2023年に4億7,090万米ドルと推定されたラジオイムノアッセイの世界市場は、2030年には5億8,710万米ドルに達し、分析期間2023-2030年のCAGRは3.2%で成長すると予測されます。本レポートで分析したセグメントの1つであるラジオイムノアッセイ試薬＆キットは、CAGR 3.4％を記録し、分析期間終了までに4億5,870万米ドルに達すると予測されます。ラジオイムノアッセイ分析装置セグメントの成長率は、分析期間中CAGR 2.6％と推定されます。

米国市場は1億2,560万米ドルと推定、中国はCAGR2.7％で成長予測

米国のラジオイムノアッセイ市場は、2023年に1億2,560万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 2.7%で推移し、2030年には市場規模9,170万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.1%と2.6%と予測されています。欧州では、ドイツがCAGR 3.3%で成長すると予測されています。

世界のラジオイムノアッセイ市場- 主要動向と促進要因まとめ

ラジオイムノアッセイ：診断検査に革命をもたらす

ラジオイムノアッセイ（RIA）は、一般的に血液や尿などのサンプル中の特定の抗原やホルモンの濃度を測定するために使用される高感度ラボ技術です。この方法では、標的分子に結合する放射性標識抗原または抗体を使用するため、対象物質の正確な定量が可能です。RIAは臨床検査室で、ホルモン障害、感染症、がんを含む様々な病状の検出やモニタリングに広く用いられています。高い感度と特異性を持つこの技術は、インスリン、甲状腺ホルモン、生殖ホルモンなどの低レベルのホルモンの検出や、腫瘍マーカーやその他のバイオマーカーの測定に特に有用です。RIAは、病気の診断、治療計画、モニタリングに不可欠な正確で信頼性の高い結果を提供することで、診断検査に革命をもたらしました。

技術の進歩はどのようにラジオイムノアッセイを向上させているか？

技術の進歩は、ラジオイムノアッセイの性能、安全性、利便性を著しく向上させ、幅広い診断用途に効果的です。放射性同位元素標識の革新は、RIA試薬の安定性と感度を向上させ、より正確で一貫した結果を可能にしました。自動化されたRIAシステムの開発により、検査工程が合理化され、アッセイ調製と分析に必要な時間と労力が削減されるとともに、人為的ミスのリスクも最小限に抑えられています。アッセイ小型化とマイクロプレート形式の使用における進歩は、RIAのスループットを向上させ、複数サンプルの同時分析を可能にし、研究室の効率を改善しました。さらに、RIAと酵素免疫測定法（EIA）や化学発光測定法などの他の診断技術との統合により、検出・定量できる分析物の範囲が拡大し、より包括的な診断情報が得られるようになった。このような技術的向上が、世界中の臨床検査室における高度なRIAシステムの採用を後押ししています。

医療診断におけるラジオイムノアッセイの主な用途と利点は何ですか？

ラジオイムノアッセイは幅広い診断アプリケーションに使用され、医療検査の正確性、信頼性、効率性を高める数多くの利点を提供します。内分泌学では、RIAは糖尿病、甲状腺疾患、生殖器疾患などの患者のホルモンレベルの測定に不可欠であり、診断や治療計画に重要な情報を提供します。腫瘍学では、RIAは腫瘍マーカーを検出し、がん治療の有効性をモニターするために使用され、早期介入と個別化治療アプローチを可能にします。この技術は感染症検査にも有用で、患者サンプル中のウイルスや細菌抗原の存在を検出し、感染症の迅速な診断と管理に役立てることができます。さらに、RIAは薬物動態学において、血液中の薬物濃度を測定するために使用され、適切な投与量を確保し、治療反応をモニタリングします。RIAの主な利点には、高い感度、特異性、低濃度の分析物を検出する能力があり、臨床診断において不可欠なツールとなっています。

ラジオイムノアッセイ市場の成長を促進する要因は？

ラジオイムノアッセイ市場の成長は、いくつかの要因によって牽引されています。がん、糖尿病、ホルモン異常などの慢性疾患の有病率の増加は、これらの疾患が効果的な管理のために精密な診断検査を必要とすることから、重要な促進要因となっています。放射性同位元素標識、自動化、アッセイ小型化における技術的進歩も、RIAシステムの性能と効率を高めることで市場成長を後押ししています。個別化医療と標的治療に対する需要の高まりは、RIAの採用をさらに後押ししています。これらの技術は、個別化された治療計画のための重要な情報を提供するからです。さらに、感染症検査や薬物動態学などの分野でRIAの用途が拡大していることも、ヘルスケアプロバイダーがより正確で信頼性の高い診断ツールを求めていることから、市場の成長に寄与しています。診断精度の向上とヘルスケアコストの削減への関心の高まりも、臨床検査室における高度なRIAシステムの採用を後押ししています。これらの要因は、診断技術における継続的な技術革新と相まって、ラジオイムノアッセイ市場の持続的成長を後押ししています。

調査対象企業の例（注目の44社）

  • Beckman Coulter, Inc.
  • Berthold Technologies GmbH & Co. KG
  • Cisbio Bioassays
  • DiaSorin SpA
  • Diasource Immunossays S.A
  • DRG International, Inc.
  • Euro Diagnostica AB
  • IBL International GmbH
  • Izotop
  • MilliporeSigma
  • MP Biomedicals LLC
  • PerkinElmer, Inc.
  • Stratec Biomedical AG

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP14331

Global Radioimmunoassays Market to Reach US$587.1 Million by 2030

The global market for Radioimmunoassays estimated at US$470.9 Million in the year 2023, is expected to reach US$587.1 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. Radioimmunoassay Reagents & Kits, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$458.7 Million by the end of the analysis period. Growth in the Radioimmunoassay Analyzers segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$125.6 Million While China is Forecast to Grow at 2.7% CAGR

The Radioimmunoassays market in the U.S. is estimated at US$125.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$91.7 Million by the year 2030 trailing a CAGR of 2.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Radioimmunoassays Market - Key Trends and Drivers Summarized

Radioimmunoassays: Revolutionizing Diagnostic Testing

Radioimmunoassays (RIAs) are highly sensitive laboratory techniques used to measure the concentration of specific antigens or hormones in a sample, typically blood or urine. The method involves the use of radioactively labeled antigens or antibodies that bind to the target molecule, allowing for precise quantification of the substance of interest. RIAs are widely used in clinical laboratories for the detection and monitoring of various medical conditions, including hormonal disorders, infectious diseases, and cancer. The technique's high sensitivity and specificity make it particularly valuable for detecting low levels of hormones, such as insulin, thyroid hormones, and reproductive hormones, as well as for measuring tumor markers and other biomarkers. RIAs have revolutionized diagnostic testing by providing accurate and reliable results that are critical for disease diagnosis, treatment planning, and monitoring.

How Are Technological Advancements Enhancing Radioimmunoassays?

Technological advancements have significantly improved the performance, safety, and convenience of radioimmunoassays, making them more effective for a wide range of diagnostic applications. Innovations in radioisotope labeling have enhanced the stability and sensitivity of RIA reagents, allowing for more accurate and consistent results. The development of automated RIA systems has streamlined the testing process, reducing the time and labor required for assay preparation and analysis, while also minimizing the risk of human error. Advances in assay miniaturization and the use of microplate formats have increased the throughput of RIAs, enabling the simultaneous analysis of multiple samples and improving laboratory efficiency. Additionally, the integration of RIA with other diagnostic techniques, such as enzyme immunoassays (EIAs) and chemiluminescent assays, has expanded the range of analytes that can be detected and quantified, providing more comprehensive diagnostic information. These technological improvements are driving the adoption of advanced RIA systems in clinical laboratories worldwide.

What Are the Key Applications and Benefits of Radioimmunoassays in Medical Diagnostics?

Radioimmunoassays are used in a wide range of diagnostic applications, offering numerous benefits that enhance the accuracy, reliability, and efficiency of medical testing. In endocrinology, RIAs are essential for measuring hormone levels in patients with conditions such as diabetes, thyroid disorders, and reproductive health issues, providing critical information for diagnosis and treatment planning. In oncology, RIAs are used to detect tumor markers and monitor the effectiveness of cancer therapies, allowing for early intervention and personalized treatment approaches. The technique is also valuable in infectious disease testing, where it can detect the presence of viral or bacterial antigens in patient samples, aiding in the rapid diagnosis and management of infections. Additionally, RIAs are used in pharmacokinetics to measure drug levels in the blood, ensuring appropriate dosing and monitoring therapeutic responses. The primary benefits of RIAs include their high sensitivity, specificity, and ability to detect low concentrations of analytes, making them indispensable tools in clinical diagnostics.

What Factors Are Driving the Growth in the Radioimmunoassays Market?

The growth in the Radioimmunoassays market is driven by several factors. The increasing prevalence of chronic diseases, such as cancer, diabetes, and hormonal disorders, is a significant driver, as these conditions require precise diagnostic testing for effective management. Technological advancements in radioisotope labeling, automation, and assay miniaturization are also propelling market growth by enhancing the performance and efficiency of RIA systems. The rising demand for personalized medicine and targeted therapies is further boosting the adoption of RIAs, as these techniques provide critical information for individualized treatment planning. Additionally, the expanding applications of RIAs in areas such as infectious disease testing and pharmacokinetics are contributing to market growth, as healthcare providers seek more accurate and reliable diagnostic tools. The growing focus on improving diagnostic accuracy and reducing healthcare costs is also supporting the adoption of advanced RIA systems in clinical laboratories. These factors, combined with continuous innovation in diagnostic technology, are driving the sustained growth of the Radioimmunoassays market.

Select Competitors (Total 44 Featured) -

  • Beckman Coulter, Inc.
  • Berthold Technologies GmbH & Co. KG
  • Cisbio Bioassays
  • DiaSorin SpA
  • Diasource Immunossays S.A
  • DRG International, Inc.
  • Euro Diagnostica AB
  • IBL International GmbH
  • Izotop
  • MilliporeSigma
  • MP Biomedicals LLC
  • PerkinElmer, Inc.
  • Stratec Biomedical AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Radioimmunoassays - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Sensitive and Specific Diagnostic Tests Propels Market Growth
    • Increasing Use in Clinical and Research Laboratories Expands Addressable Market Opportunity
    • Technological Advancements in Radioimmunoassay Techniques Strengthen Market Position
    • Growing Focus on Early Disease Detection and Monitoring Drives Adoption of Radioimmunoassays
    • Surge in Demand for Hormone and Tumor Marker Testing Generates New Opportunities
    • Development of Automated and High-Throughput Assay Systems Sustains Market Growth
    • Expanding Applications in Endocrinology and Oncology Throws Spotlight on Market Potential
    • Growth in Personalized Medicine and Targeted Therapies Spurs Demand for Radioimmunoassays
    • Rising Adoption of Radioimmunoassays in Academic and Research Institutions Propels Market Expansion
    • Surge in Demand for Radioimmunoassays in Infectious Disease Testing Expands Market Horizons
    • Growing Awareness of the Benefits of Radioimmunoassays in Rare Disease Diagnosis Drives Market Adoption
    • Innovations in Radioactive Labeling and Detection Technologies Generate New Market Opportunities
    • Rising Demand for Radioimmunoassays in Emerging Healthcare Markets Throws Spotlight on Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Radioimmunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Radioimmunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Radioimmunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Reagents & Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Analyzers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Clinical Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Radioimmunoassays Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Clinical Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • JAPAN
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • CHINA
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • EUROPE
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Radioimmunoassays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Radioimmunoassays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • FRANCE
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • GERMANY
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Radioimmunoassays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by Type - Reagents & Kits and Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Radioimmunoassays by Type - Reagents & Kits and Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of World 16-Year Perspective for Radioimmunoassays by Type - Percentage Breakdown of Value Sales for Reagents & Kits and Analyzers for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Radioimmunoassays by End-Use - Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Radioimmunoassays by End-Use - Percentage Breakdown of Value Sales for Hospitals, Pharmaceutical, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Radioimmunoassays by Application - Research and Clinical Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Radioimmunoassays by Application - Research and Clinical Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Radioimmunoassays by Application - Percentage Breakdown of Value Sales for Research and Clinical Diagnostics for the Years 2014, 2024 & 2030

IV. COMPETITION